Mortality after inpatient treatment for diarrhea in children: a cohort study

Alison Talbert1, Moses Ngari2,3, Evasius Bauni2

  • 1KEMRI/Wellcome Trust Research Programme, Centre for Geographic Medicine Research - Coast, PO Box 230, Kilifi, 80108, Kenya. atalbert@kemri-wellcome.org.

BMC Medicine
|January 29, 2019
PubMed

Insights

Children discharged from hospitals in low-resource settings face high mortality risks, especially from diarrhea. Malnutrition, HIV, and pneumonia are key factors increasing mortality risk both during hospitalization and after discharge.

Area of Science:

  • Pediatric Infectious Diseases
  • Global Child Health
  • Epidemiology

Background:

  • Children in resource-poor settings are at high risk of death post-discharge.
  • Diarrheal diseases are a significant risk factor for post-discharge mortality in children.

Purpose of the Study:

  • To estimate the incidence of post-discharge mortality in children admitted with diarrhea.
  • To identify demographic, clinical, and biochemical factors associated with inpatient and post-discharge mortality.

Main Methods:

  • Retrospective cohort study of children (2-59 months) admitted with diarrhea (2007-2015).
  • Utilized Kilifi County Hospital and Kilifi Health and Demographic Surveillance System (KHDSS) data.
  • Employed log-binomial and Cox proportional regression models to identify risk factors.

Main Results:

  • Overall inpatient mortality was 4.6%; post-discharge mortality was 2.1% (21.4 deaths per 1000 child-years).
  • Severe pneumonia, HIV, low mid-upper arm circumference (MUAC), and bacteremia were associated with increased inpatient and post-discharge mortality.
  • Prior admission and chest wall indrawing were linked to post-discharge mortality, while circulatory impairment, sepsis, and abnormal electrolytes were linked to inpatient mortality.

Conclusions:

  • Findings highlight the critical need for improved services for malnutrition and HIV in children.
  • Further research is needed to understand causal pathways and develop interventions to reduce child mortality in resource-poor settings.
Abstract

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
711
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
292
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
993
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
944